Navigation Links
Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009
Date:4/1/2009

ADDISON, Texas, April 1 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal(TM) Transforming Powder Dressing, and data on the physical properties of Altrazeal(TM) Silver will be presented at the annual APWCA National Clinical Conference in Philadelphia, April 2-5, 2009. The work will be presented in podium presentations and with posters on display during the meeting.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "Since the launch of Altrazeal(TM) in June 2008, we have accumulated extensive clinical experience across all wound types. The presentation of this data in a formal forum is a reflection of the execution of an important part of our 2009 business strategy."

Dr. Brock Liden, DPM of the Berger Health Care Center in Circleville, Iowa, will discuss at one podium presentation a talk titled "Treatment methods and experience with a novel aggregating powder dressing." In this presentation, Dr. Liden will detail his experiences and best clinical practice using Altrazeal(TM), application techniques, and what to expect when applying and treating wounds with the dressing.

In addition, clinical evidence using Altrazeal(TM) in treatment of diabetic foot ulcers, surgical wounds, and difficult to treat wounds such as those on sickle cell patients or patients afflicted with lymphangioma or pyoderma will be presented. A total of five posters detailing clinical evidence of Altrazeal(TM) will be displayed including one that shows the successful use of Altrazeal(TM) under contact casts in the treatment of diabetic foot ulcers. Commenting on the product, Dr. Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, and author of three of the posters stated, "Altrazeal(TM) is proving to be a very versatile dressing in wound care. The ability to apply it for up to 30 days and combine it with other substances will have substantial impact in the wound care field."

Dr. John St. John, the Company's Vice President of Research and Development, will present a podium presentation on the development path of Altrazeal(TM) and the Altrazeal(TM) family of wound dressings.

In addition, another poster will be presented with data on the biocompatibility and physical properties of Altrazeal(TM) Silver. The Company will also exhibit Altrazeal(TM) Transforming Powder Dressing at a booth during APWCA, demonstrating the mechanism of action and ease of application for wound care professionals in attendance.

Details of APWCA are available online at http://www.apwca.org/apwca2009.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, ease of application, success in wound healing, and suitability of Altrazeal(TM) and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
2. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
3. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
4. Upcoming Symposium to Bridge the Gap between Osteoporosis Research and its Applications to Clinical Practice with Focus on Secondary Osteoporosis, Osteoporosis in Men, and Lessons from Space Travel for Improving Bone Health
5. By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
6. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
7. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
8. Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
9. Task Force Recommends Screening Adolescents for Clinical Depression
10. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
11. Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
(Date:3/29/2017)... OK (PRWEB) , ... March 29, 2017 , ... ... now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with ... straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a clinical ... through treatment, today announced that Carmine N. Stengone , president ... at the Needham & Company 16 th Annual Healthcare Conference ... PDT) at the Westin Grand Central Hotel in New ... ...
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... March 29, 2017 Today, CVS Health officials (NYSE: ... Reynolds , Department of Public Health Director Gerd Clabaugh ... Lukan in announcing the availability of the opioid overdose-reversal ... in Iowa.  CVS Health has established a standing order with ... Pharmacy to expand access to the medication in the state.   ...
Breaking Medicine Technology: